Inotersen PKPD model
Indication: Hereditary transthyretin-mediated amyloidosis with polyneuropathy
Population PK/PD simulator for inotersen, a subcutaneous antisense oligonucleotide that reduces transthyretin production by targeting TTR mRNA. Includes exposure-response modeling for TTR lowering in hATTR-PN.
Drug Overview
Clinical Context
- Molecular Target
- TTR mRNA
- Drug Class
- Antisense Oligonucleotide (ASO)
- Therapeutic Area
- Hereditary Transthyretin Amyloidosis (hATTR)
- Indication
- Hereditary transthyretin-mediated amyloidosis with polyneuropathy
- Route of Administration
- Subcutaneous
Model Information
- Model Type
- Population PK/PD
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Inotersen allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK/PD model characterizes the pharmacokinetics of this antisense oligonucleotide (aso) following subcutaneous administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Inotersen PK simulator?
This is a free, interactive pharmacokinetic simulator for Inotersen used in Hereditary transthyretin-mediated amyloidosis with polyneuropathy. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Inotersen belong to?
Inotersen is classified as a Antisense Oligonucleotide (ASO) that targets TTR mRNA. It is used in the Hereditary Transthyretin Amyloidosis (hATTR) therapeutic area.
What route of administration does this model simulate?
This simulator models Subcutaneous administration of Inotersen. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK/PD model. PK/PD models link drug concentrations to pharmacological effects, allowing exploration of exposure-response relationships.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Ready to Simulate?
Launch the Inotersen simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community